These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23327964)

  • 1. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
    Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
    Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
    Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
    Zhu XL; Zhou XY; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
    Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
    Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
    Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
    Sheu SY; Schwertheim S; Worm K; Grabellus F; Schmid KW
    Mod Pathol; 2007 Jul; 20(7):779-87. PubMed ID: 17464312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.
    Rao PJ; Vardhini NV; Parvathi MV; Murthy PB; Sudhakar G
    Tumour Biol; 2014 Oct; 35(10):9539-48. PubMed ID: 24957039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.